<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118961</url>
  </required_header>
  <id_info>
    <org_study_id>BKD1A</org_study_id>
    <nct_id>NCT02118961</nct_id>
  </id_info>
  <brief_title>Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents</brief_title>
  <official_title>Confirmatory Study to Evaluate the Immunogenicity of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP Vaccine, BK1301) as a Booster in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Foundation for Microbial Diseases of Osaka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a
      booster dose in adolescents.

      The purposes of this study are as follows:

        -  To confirm the non-inferiority of BK1301 to Adsorbed Diphtheria-Tetanus Combined Toxoid
           (DT toxoid) with respect to booster responses for anti-diphtheria toxoid (anti-D) and
           anti-tetanus toxoid (anti-T) antibodies

        -  To confirm that booster responses for anti-pertussis toxoid (anti-PT) and
           anti-Filamentous Hemagglutinin (anti-FHA) antibodies are more than 80% of participants
           received BK1301
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies</measure>
    <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
    <description>Booster response was defined as post titer ≥ 0.4 IU/mL and post/pre titer ≥ 4 increase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Booster Responses for Anti-pertussis Toxoid (Anti-PT) and Anti-Filamentous Hemagglutinin (Anti-FHA) Antibodies</measure>
    <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
    <description>Booster response was defined as post titer ≥ 20 EU/mL and post/pre titer ≥ 4 increase in a subject with pre titer &lt; 20 EU/mL, or post/pre titer ≥ 2 increase in a subject with pre titer ≥ 20 EU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-D and Anti-T Antibody Titers Above Protocol Defined Cut-off Values</measure>
    <time_frame>28-42 days after vaccination</time_frame>
    <description>Protocol defined cut-off values were 0.1 IU/mL for anti-D and 0.01 IU/mL for anti-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-PT and Anti-FHA Antibody Titers Above Protocol Defined Cut-off Values</measure>
    <time_frame>28-42 days after vaccination</time_frame>
    <description>Protocol defined cut-off values were 10 EU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Anti-D and Anti-T Antibodies</measure>
    <time_frame>28-42 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Anti-PT and Anti-FHA Antibodies</measure>
    <time_frame>28-42 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer Ratios of Anti-D and Anti-T Antibodies</measure>
    <time_frame>pre vaccination and 28-42 days after vaccination</time_frame>
    <description>Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer Ratios of Anti-PT and Anti-FHA Antibodies</measure>
    <time_frame>pre vaccination and 28-42 days after vaccination</time_frame>
    <description>Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>28-42 days following vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">446</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>BK1301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DT toxoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)</intervention_name>
    <description>0.5 mL, subcutaneous injection</description>
    <arm_group_label>BK1301</arm_group_label>
    <other_name>TRIBIK®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)</intervention_name>
    <description>0.1 mL, subcutaneous injection</description>
    <arm_group_label>DT toxoid</arm_group_label>
    <other_name>DTBIK®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 11 or 12 years on the day of injection

          -  Received 3 or 4 doses of DTaP vaccine

        Exclusion Criteria:

          -  History of pertussis, diphtheria, tetanus

          -  History of anaphylaxis to vaccine components

          -  Serious conditions or diseases of the heart, vein, blood, respiratory, hepar, kidney,
             digestive system, psychiatric or nervous system

          -  Transfused or received gamma globulin within 3 months, or received high-dose gamma
             globulin within 6 months before the day of injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shintaro Okada, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Osaka University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Itoshima-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inverstigational site</name>
      <address>
        <city>Kumagaya-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inverstigational site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <results_first_submitted>May 16, 2016</results_first_submitted>
  <results_first_submitted_qc>September 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2016</results_first_posted>
  <last_update_submitted>November 24, 2016</last_update_submitted>
  <last_update_submitted_qc>November 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>DTaP vaccine</keyword>
  <keyword>Adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BK1301</title>
          <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
        </group>
        <group group_id="P2">
          <title>DT Toxoid</title>
          <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BK1301</title>
          <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
        </group>
        <group group_id="B2">
          <title>DT Toxoid</title>
          <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="224"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="446"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies</title>
        <description>Booster response was defined as post titer ≥ 0.4 IU/mL and post/pre titer ≥ 4 increase.</description>
        <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>DT Toxoid</title>
            <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies</title>
          <description>Booster response was defined as post titer ≥ 0.4 IU/mL and post/pre titer ≥ 4 increase.</description>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.5" lower_limit="97.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="96.1" upper_limit="99.7"/>
                    <measurement group_id="O2" value="97.3" lower_limit="94.2" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Booster Responses for Anti-pertussis Toxoid (Anti-PT) and Anti-Filamentous Hemagglutinin (Anti-FHA) Antibodies</title>
        <description>Booster response was defined as post titer ≥ 20 EU/mL and post/pre titer ≥ 4 increase in a subject with pre titer &lt; 20 EU/mL, or post/pre titer ≥ 2 increase in a subject with pre titer ≥ 20 EU/mL.</description>
        <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
        <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Booster Responses for Anti-pertussis Toxoid (Anti-PT) and Anti-Filamentous Hemagglutinin (Anti-FHA) Antibodies</title>
          <description>Booster response was defined as post titer ≥ 20 EU/mL and post/pre titer ≥ 4 increase in a subject with pre titer &lt; 20 EU/mL, or post/pre titer ≥ 2 increase in a subject with pre titer ≥ 20 EU/mL.</description>
          <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" lower_limit="86.5" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" lower_limit="87.0" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-D and Anti-T Antibody Titers Above Protocol Defined Cut-off Values</title>
        <description>Protocol defined cut-off values were 0.1 IU/mL for anti-D and 0.01 IU/mL for anti-T.</description>
        <time_frame>28-42 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>DT Toxoid</title>
            <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-D and Anti-T Antibody Titers Above Protocol Defined Cut-off Values</title>
          <description>Protocol defined cut-off values were 0.1 IU/mL for anti-D and 0.01 IU/mL for anti-T.</description>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-PT and Anti-FHA Antibody Titers Above Protocol Defined Cut-off Values</title>
        <description>Protocol defined cut-off values were 10 EU/mL.</description>
        <time_frame>28-42 days after vaccination</time_frame>
        <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-PT and Anti-FHA Antibody Titers Above Protocol Defined Cut-off Values</title>
          <description>Protocol defined cut-off values were 10 EU/mL.</description>
          <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
          <units>percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Anti-D and Anti-T Antibodies</title>
        <time_frame>28-42 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>DT Toxoid</title>
            <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Anti-D and Anti-T Antibodies</title>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.856" lower_limit="18.221" upper_limit="23.872"/>
                    <measurement group_id="O2" value="15.581" lower_limit="13.748" upper_limit="17.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.378" lower_limit="11.838" upper_limit="15.118"/>
                    <measurement group_id="O2" value="11.638" lower_limit="10.348" upper_limit="13.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Anti-PT and Anti-FHA Antibodies</title>
        <time_frame>28-42 days after vaccination</time_frame>
        <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Anti-PT and Anti-FHA Antibodies</title>
          <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.15" lower_limit="210.65" upper_limit="276.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344.46" lower_limit="309.72" upper_limit="383.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer Ratios of Anti-D and Anti-T Antibodies</title>
        <description>Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers</description>
        <time_frame>pre vaccination and 28-42 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>DT Toxoid</title>
            <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios of Anti-D and Anti-T Antibodies</title>
          <description>Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers</description>
          <units>titer ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.5" lower_limit="107.8" upper_limit="175.5"/>
                    <measurement group_id="O2" value="106.3" lower_limit="83.9" upper_limit="134.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="38.9" upper_limit="59.0"/>
                    <measurement group_id="O2" value="44.3" lower_limit="36.4" upper_limit="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer Ratios of Anti-PT and Anti-FHA Antibodies</title>
        <description>Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers</description>
        <time_frame>pre vaccination and 28-42 days after vaccination</time_frame>
        <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios of Anti-PT and Anti-FHA Antibodies</title>
          <description>Ratios were calculated as 28-42 days after vaccination titers over pre vaccination titers</description>
          <population>The Outcome Measure was only pre-specified for the BK1301 Arm/Group.</population>
          <units>titer ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="10.5" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7.2" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <time_frame>28-42 days following vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BK1301</title>
            <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>DT Toxoid</title>
            <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1"/>
                    <measurement group_id="O2" value="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BK1301</title>
          <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301): 0.5 mL, subcutaneous injection</description>
        </group>
        <group group_id="E2">
          <title>DT Toxoid</title>
          <description>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid): 0.1 mL, subcutaneous injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk / Clinical Development counter</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation / The Research Foundation for Microbial Diseases of Osaka University</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp/clinicaldevelopment@mail.biken.or.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

